Form D · Other

Nautilus Biotechnology, Inc.

Seattle, WA · CIK 0001808805

Offering snapshot reported Jun 22, 2021 · SEC filing

Reported sold
$200M
Offering amount: $200M
Investors reported
38
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 9, 2021
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 22, 2021Initial$200,000,000No comparison38SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$2M
Finders' fees
$0
Form D file number
021-403839
$1,000,000 in commission fees were paid to each Goldman Sachs & Co. LLC and Jefferies LLC.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Jefferies LLC2347
Goldman Sachs & Co. LLC361

Source: Form D, filed Jun 22, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Michael Altman Director
Melissa Epperly Director
Parag Mallick Director, Executive
Matthew S. Mc Ilwain Director
Anna Mowry Executive
Matthew Murphy Executive
Farzad Nazem Director
Nicholas Nelson Executive
Vijay Pande Director
Sujal Patel Director, Executive
Matthew Posard Director
Subra Sankar Executive

Issuer details

Industry: Other (See others in industry)

Address:
425 Pontius Ave N, Ste 202
Seattle, WA, 98109